FFPM

Zevra Therapeutics Appoints Global Medical Leader, Adrian Quartel, M.D., FFPM, as Chief Medical Officer

Retrieved on: 
Thursday, January 4, 2024

CELEBRATION, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced the appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer.

Key Points: 
  • CELEBRATION, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced the appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer.
  • Dr. Quartel brings more than 20 years of experience in the international pharmaceutical industry with senior roles in clinical development, pharmacovigilance and medical affairs.
  • "It is an honor to welcome Dr. Quartel to our team during an exciting period of growth for Zevra after our recent acquisition of Acer Therapeutics and the expansion of our rare disease portfolio,” said Neil F. McFarlane, President and Chief Executive Officer of Zevra.
  • Prior to that, he was the Chief Medical Officer at Adamas Pharmaceuticals, a company focused on drug development for neurological diseases.

MAPLIGHT THERAPEUTICS APPOINTS TIM GARNETT, M.D. TO BOARD OF DIRECTORS

Retrieved on: 
Monday, July 24, 2023

SAN FRANCISCO, July 24, 2023 /PRNewswire/ -- MapLight Therapeutics, a clinical-stage biopharmaceutical company working to develop targeted, novel therapeutics to improve the lives of people with brain disorders, today announced the appointment of Tim Garnett, M.D. to its Board of Directors. Dr. Garnett is a pharmaceutical executive with decades of experience in drug development and strategic portfolio management.

Key Points: 
  • SAN FRANCISCO, July 24, 2023 /PRNewswire/ -- MapLight Therapeutics, a clinical-stage biopharmaceutical company working to develop targeted, novel therapeutics to improve the lives of people with brain disorders, today announced the appointment of Tim Garnett, M.D.
  • Dr Garnett has served on multiple boards and is currently Board Chair of Ophirex, a Board Member of Carmot Therapeutics and a member of the Advisory Panel of Cambridge Innovation Capital.
  • "I am proud to join MapLight's Board of Directors as the company moves multiple drug candidates through development and on to registrational trials," said Tim Garnett, MD.
  • "MapLight has a promising pipeline of novel assets and a talented leadership team of distinguished neuroscience veterans unique within biopharma.

AVROBIO Announces Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis at the ASGCT 26th Annual Meeting

Retrieved on: 
Thursday, May 18, 2023

These data are being presented at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Los Angeles, California, on May 18, 2023.

Key Points: 
  • These data are being presented at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Los Angeles, California, on May 18, 2023.
  • “We are excited about moving this investigational gene therapy closer to patients.”
    In addition to the data presented, the Company also announced positive and productive meetings with the U.K.
  • Preliminary data from this trial suggest that this HSC gene therapy is well tolerated, with no AEs related to the drug product to date.
  • An oral presentation by Dr. Cherqui on these data, “Phase 1/2 Clinical Trial of Autologous Hematopoietic Stem and Progenitor Cell Gene Therapy for Cystinosis,” will occur today at 3:45 PM PT in the session Metabolic, Storage, Endocrine, Liver and Gastrointestinal Disease II of the ASGCT Annual Meeting.

WesternU College of Podiatric Medicine celebrates 100% match rate for 10 consecutive years

Retrieved on: 
Thursday, March 23, 2023

POMONA, Calif., March 23, 2023 /PRNewswire-PRWeb/ -- For graduating medical students in Western University of Health Sciences' College of Podiatric Medicine (CPM), Match Day is a transformative, life-changing moment. The anxiety-filled day begins with reflections of personal endurance, hard work and self-sacrifice that instantly changes to excitement, joy and smiles learning that their journey at WesternU has made their dream come true: becoming a physician.

Key Points: 
  • POMONA, Calif., March 23, 2023 /PRNewswire-PRWeb/ -- For graduating medical students in Western University of Health Sciences' College of Podiatric Medicine (CPM), Match Day is a transformative, life-changing moment.
  • Since 1976, the Central Application Service for Podiatric Residencies has coordinated this annual rite of passage for podiatric medical and surgical residencies.
  • CPM continues to keep its promise of leading the way in inspiring and preparing the next generation of podiatric physicians.
  • In a moment of reflection, College of Podiatric Medicine Dean Jonathan Labovitz, DPM, FACFAS, CHCQM, thought about the bigger picture of this accomplishment.

Acer Therapeutics Announces Data Presented at Society for Inherited Metabolic Disorders Annual Meeting Identifying Preferred Urea Cycle Disorder Treatment Attributes

Retrieved on: 
Wednesday, March 22, 2023

The results of the survey showed that taste and odor were the most important attributes for both prescribing and for patient adherence and compliance .

Key Points: 
  • The results of the survey showed that taste and odor were the most important attributes for both prescribing and for patient adherence and compliance .
  • “OLPRUVA™5 leverages the well-established efficacy of sodium phenylbutyrate in an innovative dual-coating formulation designed for palatability,” said Adrian Quartel, MD, FFPM, CMO of Acer.
  • ACER-001 for the treatment of certain UCDs is now marketed in the U.S. as OLPRUVA™ (sodium phenylbutyrate) following FDA approval in December 2022.
  • New FDA-Approved UCD Treatment Option: OLPRUVA™
    ACER-001 (sodium phenylbutyrate) was approved for the treatment of certain UCDs in December 2022 and is marketed under the brand name, OLPRUVA™.

Acer Therapeutics Announces Presentation of HCP Urea Cycle Disorder Treatment Preference Data at the Society for Inherited Metabolic Disorders Annual Meeting and Provides OLPRUVA™ Program Update

Retrieved on: 
Wednesday, March 15, 2023

NEWTON, Mass., March 15, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced data will be presented from a survey designed to quantify preferences of healthcare providers for Urea Cycle Disorders (UCDs) at the upcoming 44th Annual Meeting of the Society for Inherited Metabolic Disorders (SIMD), March 18th-21st in Salt Lake City, Utah. Results from the discrete choice experiment will be available on Acer’s website following the poster presentation at SIMD on March 19 by Dr. Robert Steiner (University of Wisconsin School of Medicine and Public Health) at https://www.acertx.com/publications-and-presentations/.

Key Points: 
  • This poster summarizes results from a web-based, quantitative survey study using a discrete choice experiment (DCE) methodology.
  • “OLPRUVA™1 leverages the well-established efficacy of sodium phenylbutyrate in an innovative dual-coating formulation designed for palatability,” said Adrian Quartel, MD, FFPM, CMO of Acer.
  • ACER-001 for the treatment of UCDs is now marketed in the U.S. as OLPRUVA™ (sodium phenylbutyrate) following FDA approval in December 2022.
  • Acer is also actively engaged in negotiations regarding access for OLPRUVA™ with the major commercial payers and state Medicaid organizations.

Ophirex Completes $37 Million Series B Financing to Advance Development of Broad-Spectrum Snakebite Treatment

Retrieved on: 
Thursday, January 5, 2023

Ophirex, Inc., a public benefit biotechnology company, today announced the successful completion of a $37 million Series B financing, led by AXA IM Prime Impact Master Fund I SCA SICAV-RAIF.

Key Points: 
  • Ophirex, Inc., a public benefit biotechnology company, today announced the successful completion of a $37 million Series B financing, led by AXA IM Prime Impact Master Fund I SCA SICAV-RAIF.
  • Ophirex recently reached full enrollment of its BRAVO (Broad-spectrum Rapid Antidote: Varespladib Oral for snakebite) study.
  • “Ophirex can make a tremendous difference in the treatment of snakebite by improving outcomes and accessibility worldwide,” said Dr. Garnett.
  • “It’s terrific to see the importance of the company’s work recognized by the quality of interest in this oversubscribed Series B financing.

EVERSANA® Names Experienced Life Sciences Leader Sy Pretorius Chief Operating Officer & President, Outsourced Solutions to Propel Next-Generation Commercialization Services Worldwide

Retrieved on: 
Monday, November 14, 2022

CHICAGO, Nov. 14, 2022 /PRNewswire/ -- EVERSANA , a pioneer of next-generation commercial services to the global life sciences industry, today named Sy Pretorius as the company's new Chief Operating Officer and President, Outsourced Solutions.

Key Points: 
  • CHICAGO, Nov. 14, 2022 /PRNewswire/ -- EVERSANA , a pioneer of next-generation commercial services to the global life sciences industry, today named Sy Pretorius as the company's new Chief Operating Officer and President, Outsourced Solutions.
  • Pretorius joins EVERSANA as it rapidly expands its global commercialization services.
  • EVERSANA is the leading independent provider of global services to the life sciences industry.
  • The company serves more than 670 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world.

Acer Therapeutics Reports Q1 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, May 16, 2022

NEWTON, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the first quarter ended March 31, 2022 and provided an update on the Companys recent corporate developments.

Key Points: 
  • NEWTON, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the first quarter ended March 31, 2022 and provided an update on the Companys recent corporate developments.
  • Proceeds from these financings will be used to advance pipeline and for general corporate purposes.
  • Cash and cash equivalents were $20.8 million as of March 31, 2022, compared to $12.7 million as of December 31, 2021.
  • Acer believes its cash and cash equivalents available as of March 31, 2022 will be sufficient to fund its currently anticipated operating and capital requirements into Q3 2022.

Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2022

Retrieved on: 
Wednesday, May 4, 2022

WALTHAM, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the first quarter of 2022.

Key Points: 
  • Ended first quarter 2022 with $381 million in cash and equivalents, providing runway through year-end 2024
    WALTHAM, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the first quarter of 2022.
  • Revenue was $2.4 million for the quarter ended March 31, 2022, compared to $3.3 million for the same quarter last year.
  • Research and development expenses were $26.5 million for the quarter ended March 31, 2022, as compared to $18.6 million for the same quarter last year.
  • General and administrative expenses were $7.6 million for the quarter ended March 31, 2022, compared to $6.0 million for the same quarter last year.